Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate and acquired resistance. Since increased clinical benefit of MAPK inhibitors (MAPKi) is associated with previous immune checkpoint therapy, we compare the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C. Anti-PD-1/L1 lead-in preceding MAPKi combination optimizes response durability by promoting pro-inflammatory polarization of macrophages and clonal expansion of interferon-γhi, and CD8+ cytotoxic and proliferative (versus CD4+ regulatory) T cells that highly express activation genes. Since therapeutic resistance of melanoma brain metastasis (MBM) limits patient survival, we demonstrate that sequencing anti-PD-1/L1 therapy before MAPKi combination suppresses MBM and improves mouse survival with robust T cell clonal expansion in both intracranial and extracranial metastatic sites. We propose clinically testing brief anti-PD-1/L1 (± anti-CTLA-4) dosing before MAPKi co-treatment to suppress therapeutic resistance.
24 August 2023 in Journal of Translational Medicine
Background: Photoreceptor degeneration underpinned by oxidative stress-mediated mitochondrial dysfunction and cell death leads to progressive and irreversible vision impairment. Drug treatments that protect against photoreceptor degeneration are currently available in the clinical settings. It has been shown that hyperoside, a flavonol glycoside, protects against neuronal loss in part by suppressing oxidative stress and maintaining the functional integrity of mitochondria. However, whether hyperoside protects against photoreceptor degeneration remains unknown. Methods: To address the pharmacological potentials of hyperoside against oxidative stress-mediated photoreceptor degeneration on molecular, cellular, structural and functional levels, multiple in vitro and in vivo methodologies were employed in the current study, including live-cell imaging, optical coherence tomography, electroretinography, histological/immunohistochemical examinations, transmission electron microscopy, RNA-sequencing and real-time qPCR. Results: The in vitro results demonstrate that hyperoside suppresses oxidative stress-mediated photoreceptor cell death in part by mitigating mitochondrial dysfunction. The in vivo results reveal that hyperoside protects against photooxidative stress-induced photoreceptor morphological, functional and ultrastructural degeneration. Meanwhile, hyperoside treatment offsets the deleterious impact of photooxidative stress on multiple molecular pathways implicated in the pathogenesis of photoreceptor degeneration. Lastly, hyperoside attenuates photoreceptor degeneration-associated microglial inflammatory activation and reactive Müller cell gliosis. Conclusions: All things considered, the present study demonstrates for the first time that hyperoside attenuates oxidative stress-induced photoreceptor mitochondrial dysfunction and cell death. The photoreceptor-intrinsic protective effects of hyperoside are corroborated by hyperoside-conferred protection against photooxidative stress-mediated photoreceptor degeneration and perturbation in retinal homeostasis, warranting further evaluation of hyperoside as a photoreceptor protective agent for the treatment of related photoreceptor degenerative diseases.
10 April 2025 in Journal of Investigative Dermatology
Langerhans cells (LCs), as epidermal-resident antigen-presenting cells, are among the first to encounter early carcinogenic changes in the skin, such as those seen in melanoma. During inflammation or cancer, circulating monocytes are recruited into the epidermis, replacing resident LCs (rLCs) that have migrated to draining lymph nodes. However, the specific roles of LC subsets in the progression of melanoma remain unclear. Here, we observed a decrease in rLCs and an increase in monocyte-derived LCs (moLCs) within melanoma tumor tissues as the disease progressed. Notably, the frequency of moLCs was higher in patients with anti-PD-1 therapy-resistant melanoma than in those responsive to the therapy. Using muLangerin-DTR transgenic and moLC-specific knockout mouse models, we demonstrated that the depletion of rLCs accelerated melanoma growth, whereas the depletion of moLCs suppressed tumor progression. Mechanistically, moLCs exhibited elevated expression of COX2-related genes compared to rLCs. TGF-β was found to activate aryl hydrocarbon receptor (AhR)-COX2 signaling in moLCs, leading to increased production of PGE2 and expression of PD-L1, which collectively contributed to the immunosuppressive effects of moLCs on CD8+CTLs. In summary, our findings highlight the functional heterogeneity of LC subsets in melanoma progression, offering deeper insights into LC biology and potential therapeutic strategies.
1 December 2020 in European Journal Of Dermatology